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Kumpulan tiedekirjasto
The human papilloma virus (HPV) is the main cause of cervical cancer in women and HPV is the
most common sexually transmitted infection. To prevent women from developing cervical cancer
there are two methods in use, the primary method being vaccination against HPV and the secon-
dary being screening. Some long term effects of screening and vaccination will not be observed
during the first decades of vaccination, and therefore predictive mathematical models serve as an
indicator of what to anticipate in the future. In this thesis we studied two types of cervical cancer,
adenocarcinoma and squamous cell carcinoma. We determined how vaccination against a virus, as-
sociated with squamous cell carcinoma, together with screening programs affects adenocarcinomas
caused by non-vaccine type HPV.
A precancerous adenocarcinoma lesion, which is located deeper in the glandular cervical tissue, is
difficult to detect directly in screening but can be found indirectly by uncovering a common type of
cervical cancer, squamous cell carcinoma, which is easier to detect in screening. These two cancers
are mostly associated with two different strains of HPV. When vaccinating against the strain that
is found in squamous cell carcinomas the elimination of the precancerous stages of squamous cell
carcinomas mean that the detection method for adenocarcinoma is impaired, which allows for a
possible increase in adenocarcinoma prevalence. In this thesis we studied this possible increase.
To predict the effect vaccination has on adenocarcinoma, we constructed a mathematical model
of two HPV types, which were associated with squamous cell carcinoma and adenocarcinoma res-
pectively. We modeled a vaccine that protects against the HPV types associated with squamous
cell carcinoma but not adenocarcinoma. The model included the simplified natural history of HPV,
the progression of the disease, the vaccination program and the screening program. For the two
virus infections we developed a deterministic compartmental progression model. In the computa-
tions we modeled a cohort of women through their lifetime and studied the precancerous findings in
screenings and the number of cancer cases in the cohort. To understand which model components
contributed to the adenocarcinoma incidence a sensitivity analysis was conducted by varying the
screening sensitivity, the force of infection and the recovery rates.
The model yielded an increase in adenocarcinomas when vaccinating against the virus associated
with squamous cell carcinoma. The incidence of adenocarcinoma correlated with the non-vaccine
type HPV infections that would otherwise be found in screenings without vaccination. The increase
in adenocarcinomas was more prominent in a sexually active population. Compared to the reduction
in squamous cell carcinoma provided by the vaccine, the adenocarcinoma increase was, although
positive, very minor.
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Chapter 1
Introduction
The human papilloma virus (HPV) is the main cause of cervical cancer in women [1]. HPV
is the most common sexually transmitted disease and most men and women are infected
by HPV during their lifetime [2]. To prevent women from developing cervical cancer
there are two intervention methods in use. The primary intervention is vaccination of
pre-adolescent girls against the most oncogenic HPV types and the secondary is screening
through Pap- or HPV-DNA tests by which lesions are detected and treated already at a
precancerous stage.
The most common type of cervical cancer is squamous cell carcinoma, which accounts
for 70% of all cervical cancers [3] and is located in mucous membrane. A less common
type of cervical cancer is adenocarcinoma, which is located in deeper glandular tissue
and accounts for approximately 10% of all cervical cancers [3]. The Pap test is a smear
test which can detect abnormal cells, indicating potential cervical cancer with moderate
sensitivity and specificity. If a smear test is positive a sample of the tissue, known as a
biopsy, is taken to confirm a carcinoma finding. Because of the adenocarcinoma location
deeper in the glandular tissue, the adenocarcinoma lesions are more difficult to detect
in screening than squamous cell carcinomas [4]. Analyzing the biopsy can reveal an
underlying adenocarcinoma located deeper in the tissue. Because of this difficulty to
detect adenocarcinoma in screening, it is rarely detected alone and usually found by
first detecting a squamous cell carcinoma nearby [5]. This means that the detection of
adenocarcinomas largely depend on the detection of squamous cell carcinomas.
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Of the over 100 HPV types the most oncogenic ones are HPV 16 and 18, which cause
approximately 70% of all cervical cancers [2, 3]. Squamous cell carcinoma is mostly
caused by HPV 16, followed by HPV 18 and HPV 45 [3]. The HPV types found in
adenocarcinomas are largely the same as in squamous cell carcinomas, but the proportion
of HPV 18 and HPV 45 infections is greater in adenocarcinomas than in squamous cell
carcinoma.
There are three prophylactic HPV vaccines on the market [6], a bivalent, a quadriva-
lent and a nonavalent vaccine. The bivalent vaccine contains virus-like particles of HPV 16
and 18, and therefore it protects against these. The quadrivalent vaccine contains virus-
like particles of HPV 16, 18 as well as the non-oncogenic types 6 and 11 and provides a
protection against all these types. The third vaccine is a nonavalent vaccine protecting
against nine HPV types, including HPV 16, 18 and 45. The nonavalent vaccine is rela-
tively new and will be replacing the quadrivalent vaccine. All the vaccines may protect
against other HPV-types too by cross protection. The bivalent and quadrivalent vaccines
have been in use in many countries approximately a decade, while the nonavalent was
approved in Europe in 2015. The bivalent vaccine provides cross protection against HPV
45 while the quadrivalent vaccine does not [7]. This means that when vaccinating with
the quadrivalent vaccine, there is no protection against HPV 45 and adenocarcinomas
caused by this virus can continue to develop despite the vaccination.
If the squamous cell carcinomas are largely eliminated as a result of vaccination with
the quadrivalent vaccine, the number of detected precancerous stages of adenocarcinoma
can decrease as a result of this. The adenocarcinomas that have been detected after
uncovering a squamous cell carcinoma in the pre-vaccination era will not be noticed when
a population is vaccinated. Therefore the number of adenocarcinomas could increase as
a result of vaccination with the quadrivalent vaccine combined with a screening program.
This raises the question about whether elimination of HPV 16 and 18 without cross
protection against HPV 45 will affect the number of adenocarcinomas caused by HPV
45. The strains would not compete, but elimination of HPV 16 and 18 could lead to an
increase in adenocarcinomas, which also would be the case if HPV 45 replaced HPV 16
and HPV 18.
The aim of this research is to investigate if and how the number of adenocarcinomas
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are affected by vaccinating a population that is also screened regularly. The aim is also
to understand how the population characteristics, such as sexual activity, as well as virus
traits, such as recovery, and screening sensitivity affect a possible increase in adenocarci-
nomas. Will the vaccination result in an increase in cancers caused by a virus that is not
eliminated through vaccination and should we be concerned about this?
To answer the questions above we construct two artificial HPV-types corresponding to
HPV 16 and 45, which are developed to determine the characteristics of the phenomena.
We develop a deterministic Markov process model to run the natural history of the two
strains and include a screening program in the model. These procedures are applied
from S. Vänskä et al [8]. We model a homogeneous age-cohort of women and compute
the number of infections, precancerous findings and cancers at each age. We perform
sensitivity analysis to get insight in how parameters contribute to the adenocarcinoma
prevalence. We wish to draw conclusions about type replacement in this simplified setting,
which could indicate what to expect in real life.
HPV vaccination programs have been in use for about a decade, and some long term
impacts have not occurred yet. Mathematical models are widely used to predict long
term outcomes and HPV has been modeled extensively during the last decades. An
overview of the consistency of mathematical models has been done by M. Brisson et
al. [9], who conclude that even though HPV models with vaccination vary in structure,
the predictions they make are consistent. The effects of a possible screening-vaccination
induced adenocarcinoma increase will not be observed clinically in many years yet, which
allows for mathematical modeling as a unique method to anticipate the prospect of type
replacement. To our knowledge there is no published work studying this specific screening-
vaccination induced adenocarcinoma increase, although type replacement relating to HPV
has been modeled by for example J. E. Tota et al [10].
Even though we model the vaccination program in this thesis, this is neither a com-
parison of the two available vaccines nor is it a study in vaccine efficacy or effectiveness.
The vaccine and vaccination programs are already thoroughly studied in the scientific
community [11, 12].
3
Chapter 2
HPV, cervical cancer and
interventions
2.1 HPV and cervical cancer
Cancer means that cells and tissues grow uncontrollably. Cancer cells can develop into
tumors and invade new tissues destroying healthy tissue when competing for resources.
Cervical cancer is mostly caused by a long lasting HPV-infection [2]. In 93% of cervical
cancer tumor findings there is detected HPV DNA [3] and the causality of HPV leading
to cervical cancer is well known and thoroughly studied [1].
Cervical cancer is the second most common cancer in the developing world, while
western Europe has had lower incidence rates since the introduction of screening programs
[4]. Cervical cancer is the fourth most common cancer and third leading cause of cancer-
related death among Finnish women aged 15 to 44 [13]. Worldwide the cervical cancer
prevalence varies highly depending on region and continent and the highest mortality
rates are in Africa and Melanesia, while Western Europe, Western Asia and Northern
Africa have much lower mortality rates [14].
The HPV virus transmits through sexual contact and almost all women and men
get infected by some HPV type during their lifetime [2]. In most cases HPV infections
go unnoticed since 95% of the infections clear in two years [15] and do not cause any
detectable symptoms. The HPV incidence, the number of new HPV infections over time,
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depends on sexual activity [16]. The sexual activity in turn depends on the age structure,
culture as well as many other factors, and therefore the population characteristics also
have an impact on the spread of HPV. Some of the HPV types found in genitalia are less
harmful and these are known as low risk HPV and typically cause genital warts. The
oncogenic HPV types are known as high risk HPV types and can cause abnormalities and
cancers in cervical tissue.
When infected with HPV, the infection is usually cleared by the immune system [15].
If a high risk HPV infection persists, there is a risk of developing cell abnormalities and
precancerous lesions, known as neoplasms. Some of the neoplasms clear spontaneously,
while others persist. If a neoplasia is of squamous cell carcinoma type, it is known as
a cervical intraepithelial neoplasia (CIN), and if it is an adenocarcinoma neoplasia, it
is known as a cervical glandular intraepithelial neoplasia (CGIN). The neoplasms can
evolve and become cancers, but also regress and clear spontaneously. The squamous
cell carcinoma is located in the mucous membrane of the cervix, while adenocarcinoma
develops deeper in the glandular tissue. For a schematic outline of the location of the
carcinomas, see Figure 2.2.
The oncogenic HPV types in cervical cancers are well known and it is also known that
different cancer types have different virus-type distributions. The HPV 16 virus is found
in 61% of all invasive cervical cancers (in 62% of squamous cell cancers and in 50% of
adenocarcinomas), HPV 18 is found in 10% of all invasive cancers (in 8% of squamous cell
cancers and in 32% of adenocarcinomas) and HPV 45 is found in 6% of all invasive cancers
(in 5% of squamous cell cancers and in 12% of adenocarcinomas) [3], see Figure 2.1.
2.2 Vaccination
Over a third of the countries in the world (71 countries) use vaccination as the primary
method to protect against cervical cancer [6]. In addition to the earlier bivalent and
quadrivalent vaccines, the fairly new nonavalent vaccine was approved in Europe in 2015
[18]. The vaccination program in Finland included HPV vaccination in 2013 [19] and the
World Health Organization (WHO) recommends vaccination against HPV as a primary
intervention [2]. The vaccine efficacy being over 90% for both the bivalent and quadriva-
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Figure 2.1: The HPV type representation in
squamous cell carcinomas and adenocarcino-
mas, values from [3].
Figure 2.2: Schematic view of the relative loca-
tion of a squamous cell carcinoma and an ade-
nocarcinoma. Adapted from [17].
lent vaccine [20, 21], the vaccine prevents from most HPV-infections of the targeted types
and from developing precancerous lesions. Vaccination is recommended before initiation
of sexual activity, since the vaccine is not offering protection against already existing
infections.
Vaccines can provide cross protection against other virus types than the targeted types.
Cross protection against HPV 31, 33 and 45 is high in the bivalent vaccine and lower in
the quadrivalent vaccine [7]. The bivalent vaccine provides cross-protection against HPV
45 infection with high efficacy (approximately 80%) and the quadrivalent vaccine with
close to zero efficacy. There is full cross protection for HPV 45 precancerous stage with
the bivalent vaccine and no protection with the quadrivalent one [7].
2.3 Screening
Screening is used as a secondary intervention to prevent HPV infections from progressing
to precancerous stages and invasive cervical cancer. The screening program in Finland
starts at age 30 and ends at age 60, and the invitations to screening come at 5 year inter-
vals, but there is additional opportunistic screening conducted at more frequent intervals
independently of the national program [22]. In the western world (Europe and US) the
intervals between screening rounds normally range between 1 and 5 years [23]. A screening
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program with treatment options and screening rounds every 3-5 years reduces the cancer
incidence significantly [2].
The Pap test was invented by the Greek scientist Georgios Papanikolaou and it is a
cytological test, while the DNA test detects HPV genes and is a primary test with Pap
triage. An abnormal Pap test is usually followed up by a colposcopy or biopsy to confirm
the finding [2]. The Pap test detects squamous cell carcinomas well, but is less efficient
in detecting adenocarcinomas [4]. As stated in chapter 1 the adenocarcinomas are mainly
found in connection with squamous cell carcinoma findings [5].
2.4 Type replacement
Viruses, and pathogens in general, respond to the environment and can evolve in order
to survive. When a common virus type is replaced by a rarer virus type, it is called type
replacement [24]. HPV strains are stable and the mutation rate is low, as opposed to e.g.
penumonia, making genotype replacement unlikely [10]. When vaccines are introduced
in a population, some non-vaccine virus types can increase in the host as a consequence
of vaccination. If the type replacement is caused by a vaccine, it is known as vaccine-
induced pathogen strain replacement, a well-known phenomenon observed for example
when vaccinating against pneumonia (Streptococcus pneumonie), influenza (Haemophilus
influenzae), meningococcus (Neisseria meningitidis) and pertussis (Bordetella pertussis)
[24].
The type replacement can also be caused by other mechanisms than vaccination. Type
replacement should not be confused with unmasking, which means that there is a falsely
assumed causality between a virus strain and a cancer type. The mechanism of screening-
and vaccination-induced adenocarcinoma increase that is researched in this thesis is not
strictly speaking type replacement, since the elimination of one virus type resulting in an
increase in another virus type related cancer would not be type replacement. Although the
"man made" mechanism implied in this thesis is not precisely biological type replacement,
it resembles type replacement closely.
The vaccines against HPV have not been in national vaccine programs for a long time
and therefore no unambiguous conclusions about type replacement have been made yet
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[25]. Cross-protection could in theory prevent from type replacement, but the discus-
sion about whether cross protection prevents type replacement is heated in the scientific
community [26, 27] and further investigation is needed to clarify the matter.
2.5 The research question in detail
The question we aim to answer is how the number of adenocarcinomas change as a con-
sequence of vaccination and screening. More precisely, will reducing the ability to detect
CGIN, because of vaccination and elimination of the squamous cell carcinomas, lead to a
significant increase in adenocarcinomas? Can we notice a phenomenon resembling type-
replacement, where the elimination of one virus strain allows for an increase in cancers
caused by another strain?
In addition to computing the change in adenocarcinomas, we will also assess the impact
different population and virus characteristics have on the number of adenocarcinomas. We
will study if there are certain conditions that amplify a change in adenocarcinoma inci-
dence. We are also interested in determining if there are limit or maximal values that
affect the number of adenocarcinomas. Therefore we aim to determine which virus traits
or which interventions affect the number of adenocarcinomas most and how substantial
the impact is on adenocarcinoma prevalence. To assess how sexual behavior affects the
number of HPV infections, precancers and cancers respectively we will compute results
with different sexual activities. We also aim to understand how different screening inter-
vals affect the number of adenocarcinomas and if these intervals have an impact on the
findings.
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Chapter 3
Methods
To compute how the number of adenocarcinomas are affected by screening and vaccina-
tion, we developed a compartmental deterministic model for cervical cancer progression
and interventions. We model the progression of a cohort of women through their lifetime
and collect the number of screening findings and cancers that appeared during the lifetime
of the cohort. The cohort enters the model at a certain age, may or may not be vacci-
nated, progresses in time, participates in screening and we study how many individuals
are in each disease state.
The natural history of the HPV virus was discretized and simplified to capture the
crucial aspects of disease progression, screening and vaccination. Studying the effects of
the input values was also an important aspect and it was essential to have the possibility
to vary inputs and easily run the model with a range of values in order to determine if
there were certain conditions that amplified a change in adenocarcinoma incidence.
To understand how the number of cancers caused by two different HPV viruses changed
with vaccination and screening, the model included two theoretical HPV types, HPVSCC
and HPVADC. In the model HPVSCC was assumed to be a virus causing squamous cell
carcinomas and HPVADC was assumed to be a virus causing adenocarcinomas. The vaccine
in our model is assumed to fully protect against HPVSCC but not against HPVADC, and
does not provide any cross protection against HPVADC either. Screening aside, the natural
histories of the two virus types were assumed independent of each other.
The reason why we use a numerical progression model instead of analyzing possible
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equilibria and stabilities of these is that the time line in reaching equilibriums might
be very long, while this study is a study of the effects of interventions in public health
in the near future. Population equilibria are not the most accurate description in this
setting because of the introduction of new vaccines with new properties replacing the older
vaccines. The discontinuity of screening is also problematic when modeling populations
analytically.
3.1 The model
3.1.1 Natural history
In the model we consider population level dynamics. This means that the focus is not on
an individual alone but on the population as a homogeneous group where the same rates
apply to all individuals. Individuals are grouped into states according to their disease
stage and proceeded from one state to another according to the outline in this section.
Consider an infection of a single-type of squamous cell carcinoma virus HPVSCC. We
define the state space to be
X = {S, I, CIN, SCC,R, V }
where S stands for susceptible, I stands for infection that has not progressed to neoplasia,
CIN stands for cervical intraepithelial neoplasia (the precancerous state), SCC stands for
squamous cell carcinoma, R stands for recovered and immune and V stands for immunized-
by-vaccination. The states in the state space are also referred to as the disease states.
For the adenocarcinoma virus HPVADC the state space is
Y = {S, I, CGIN,ADC,R, V },
where CGIN stands for cervical glandular intraepithelial neoplasia and ADC for adeno-
carcinoma, and the rest of the states are equivalent with the HPVSCC states.
The rates, or expected number of transitioning individuals between compartments per
unit of time, are indicated by arrows in Figure 3.1 and Figure 3.2 and summarized in
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S I CIN SCC V
R
λ(a) piI,SCC piCIN
ηI,SCC
ηCIN
Figure 3.1: Compartmental flow chart of a HPVSCC infection.
S I CGIN ADC V
R
λ(a) piI,ADC piCGIN
ηI,ADC
ηCGIN
Figure 3.2: Compartmental flow chart of a HPVADC infection.
Table 3.1. All the rates are type specific. Recovery is possible from the I, CIN and
CGIN states, whereas the SCC and ADC states are absorbing states and the V state is
an isolated state. We do not take background death into count in this model. See figures
3.1 and 3.2 for schematic descriptions of the natural history.
The transition from S to I is known as the force of infection. The model does not take
into count transmission dynamics but has HPV infection rate as a model input. To model
the force of infection λ we use an age dependent, HPV-like function, first presented in [8].
The value of λ at age a is
(3.1) λ(a) = K
c
(a− a0)κe−(a−a0)/θ + 0.05K
where
κ = (aM − a0)/θ and c = (κθ)κe−κ
and a0 is the entering age, K is the maximal force of infection value, aM is the age at this
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Rate Description
λ(a) Force of infection, age dependent
piI Progression rate
piCIN Symptom rate in CIN
piCGIN Symptom rate in CGIN
ηI Clearance rate from I
ηCIN Clearance rate from CIN
ηCGIN Clearance rate from CGIN
Table 3.1: Transition rates.
maximum and θ is the tail thickness. The progression rate from I to CIN is piI,SCC , the
progression rate from I to CGIN is piI,ADC , the progression from CIN to SCC is piCIN and
from CGIN to ADC is piCGIN . Clearance, also known as recovery, from I is determined by
ηI , from CIN by ηCIN and from CGIN by ηCGIN . We assumed that an infection with a
HPV type implies a life long immunity to it, which means that the R-state is a terminal
state. If a population is vaccinated, the vaccination is conducted before the entering age
a0 which means that they are in the V-state at a0. The immunity from vaccination was
also assumed lasting life long, which in turn explains why the V-state is an isolated state.
The natural history parameters, such as progression and recovery from the disease, were
assumed to be independent of age.
The differential equation system describing the HPVSCC model is
(3.2)

S˙ = −λ(a)S
I˙ = λ(a)S − piII − ηII
˙CIN = piII − piCINCIN − ηCINCIN
˙SCC = piCINCIN
R˙ = ηII + ηCINCIN
V˙ = 0
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with the initial value 
S(0) = 1
I(0) = 0
CIN(0) = 0
SCC(0) = 0
R(0) = 0
V (0) = 0
for a non-vaccinated population and

S(0) = 0
I(0) = 0
CIN(0) = 0
SCC(0) = 0
R(0) = 0
V (0) = 1
for a vaccinated population. The differential equation system for HPVADC is analogously
(3.3)

S˙ = −λ(a)S
I˙ = λ(a)S − piII − ηII
˙CGIN = piII − piCGINCGIN − ηCGINCGIN
˙ADC = piCGINCGIN
R˙ = ηII + ηCGINCGIN
V˙ = 0
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with the initial value 
S(0) = 1
I(0) = 0
CGIN(0) = 0
ADC(0) = 0
R(0) = 0
V (0) = 0
.
For this system the initial value for no vaccination does not differ from vaccination, because
HPVADC is not a vaccine type. In Equation 3.3 the V-state is redundant, and could be
left out of the equation. Although redundant, we keep the V-state in the notation for the
sake of symmetry in the two-type virus case described below.
When modeling a co-infection, where an individual can be infected with HPVSCC and
HPVADC simultaneously, the state space is X × Y with states (x, y) ∈ X × Y where x
is the disease state of HPVSCC and y is the disease state of HPVADC. There are now 36
possible HPV states in the two type state space. The co-infection model follows the idea
of the single-type model, but with type-specific rates λi, piI,i, ρi, ηIi, piCIN , piCGIN , ηCIN
and ηCGIN where i = SCC,ADC. For the co-infection model the transitions between the
disease states are determined by Equation 3.2 and Equation 3.3.
3.1.2 Time handling
The time unit in the model is one year, and all rates were defined according to this. To
propagate a cohort of women in time, we defined the time step to be ∆t = 1/52 , one
week. Time started at the model entering age a0, which was 10 in our simulation, and
ended at age an, which was 70 in our simulation. Between these ages we moved one ∆t
forward in time, propagating the cohort one week and updating it accordingly. In the
simulation, age and time coincide, so as we propagated our cohort in time, the cohort aged
according to the same time step length. A possible vaccination was conducted before a0
and the schematic idea of the time progression is sketched in Figure 3.3.
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Figure 3.3: Time progression in the model, where a0 is the entering age, before which a possible vaccine
is taken, as is a screening age and an is the exit age.
3.1.3 Transition probability matrix and updating the cohort
Suppose a cohort of women has a certain distribution on the disease states. To propagate
it one step in time, we need a matrix that gives the transition probabilities for that time
step. The process in time is a Markov chain, where the next state in time is determined
only by the current state, see Appendix B for more detailed descriptions.
Denote a two-type disease distribution by F where F = F ((x, y); a) is a discrete
probability distribution function describing the distribution on the disease states. For
simplicity, consider first a single type disease distribution F1 where F1 = F1(x; a) is a
distribution on X. In order to propagate a single-type population F1 in time from t to
t + ∆t, we compute the probability of changing state from x′ ∈ X to x ∈ X with the
number of individuals in F1(x′; t) and then sum up all the transitions to this state.
Let x and x′ be states in X and let q(x, x′; t) be the rate from x′ to x at time t, where
the rate may depend on the time t, especially the force of infection in this model. For the
sake of simplicity we leave out the t-notation and denote the rate by q(x, x′). Denote the
sum of the rates out from state x′ by
(3.4) q˜(x′) =
∑
x∈X
q(x, x′).
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The probability Px(τ) of still being in state x at τ time provided that Px(0) = 1 is
dPx(τ)
dτ
= −q˜(x)Px(τ)
and solving this ODE gives
(3.5) Px(τ) = Px(0)e−q˜(x)τ = e−q˜(x)τ .
From Equation 3.5 we get the probability of remaining in state x at time t+ ∆t, given
that we are in state x at time t, as e−q˜(x)∆t . The probability of transitioning out from
state x, which is the probability of not remaining in state x at time t + ∆t, given that
we are in state x at time t, is therefore 1 − e−q˜(x)∆t. Note also that the probability of
transitioning specifically from x′ to x in ∆t is
P (x′ to x)
P (any transition from x′) =
q(x, x′)∆t
q˜(x′)∆t =
q(x, x′)
q˜(x′) .
By combining these observations we can conclude that the probability of remaining in a
state, and the probability of a specific transition, can be summarized with the transition
probability function
(3.6) N∆t(x, x′; t) =

e−q˜(x
′)∆t if x′ = x
(1− e−q˜(x′)∆t) q(x,x′)
q˜(x′) if x
′ 6= x and q˜(x′) 6= 0
0 if x′ 6= x and q˜(x′) = 0,
where N∆t is dependent on the size of the time step ∆t and also on the current time t,
because of the force of infection being time-dependent. Note that the columns of N∆t
have to sum up to 1 to meet the constraints of a transition probability matrix. Updating
the whole cohort one time step is therefore
(3.7) F1(x; t+ ∆t) =
∑
x′∈X
N∆t((x, x′); t)F1(x′; t).
or simply F1(t + ∆t) = N∆tF1(t), where N∆t is the transition probability function, also
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known as the natural history function.
Propagating a two-type cohort matrix F is similar to the one described by Equa-
tion 3.7, but now we have two progression matrices NSCC∆t and NADC∆t . The assumption
that the two virus types are independent in their progression between states means that
updating the cohorts can be done by two progression matrices,
(3.8) NSCC∆t ((x, x′); t) =

e−q˜SCC(x
′)∆t if x′ = x
(1− e−qSCC(x′)∆t) qSCC(x,x′)
q˜SCC(x′) if x
′ 6= x if x′ 6= x and q˜(x′) 6= 0
0 if x′ 6= x and q˜SCC(x′) = 0
and
(3.9) NADC∆t ((y, y′); t) =

e−q˜ADC(y
′)∆t if y′ = y
(1− e−qADC(y′)∆t) qADC(y,y′)
q˜ADC(y′) if y
′ 6= y if y′ 6= y and q˜(y′) 6= 0
0 if y′ 6= y and q˜ADC(y′) = 0
with the type-specific rates qSCC and qADC , and with x, x′ ∈ X and y, y′ ∈ Y . Perturbing a
two-type distribution with ∆t follows exactly the same idea as in equation Equation 3.7.
Applying Equation 3.7 on both HPV types gives FSCC(t + ∆t) = NSCC∆t FSCC(t) and
FADC(t + ∆t) = NADC∆t FADC(t) and with the two-type distribution F = FSCCF TACD it
yields
FSCC(t+ ∆t)FADC(t+ ∆t)T = (NSCC∆t FSCC(t))(NADC∆t FADC(t))T
= NSCC∆t FSCC(t)FADC(t)T (NADC∆t )T
= NSCC∆t F (t)(NADC∆t )T
which gives
(3.10) F (t+ ∆t) = NSCC∆t F (t)(NADC∆t )T .
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Invitation
to screening
[F ]
Test
[pattF ]
No test
[(1 − patt)F ]
Treatment
[T (spattF )]
No treatment
[(1 − s)pattF ]
Attends Does not attend
Positive Negative
Figure 3.4: Screening scheme. F is the population, patt is the attendance probability and s is the screening
sensitivity.
3.1.4 Screening
When a woman is at a screening age, she attends screening with a certain probability.
Let the screening ages be a set of pre-determined ages,
As = {as1, as2, . . . , asn}.
The screening scheme implemented in our model is presented in Figure 3.4. The prob-
ability of an individual attending a screening is denoted by patt ∈ [0, 1] and we assumed
that the probability of attending screening is independent of age. A woman attending
screening goes through a screening test and if she has developed a neoplasia, the test
shows it with a state-dependent sensitivity sSCC(x) ∈ [0, 1], x ∈ X for HPVSCC and
sADC(y) ∈ [0, 1], y ∈ Y for HPVADC. For a co-infection with HPVSCC and HPVADC the
sensitivity in state (x, y) is determined by
(3.11) s(x, y) = 1− (1− sSCC(x))(1− sADC(y)) where x ∈ X and y ∈ Y,
where sSCC and sADC are the screening sensitivities for the types x and y alone.
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In the model, only the CIN- and CGIN-state individuals are detected in screening. The
I-state infection is not yet detected in tests and the C-state is considered a symptomatic
state, which means that it is detected by symptoms and treated outside the screening pro-
gram. Upon detection of a positive result the individual is treated and becomes immune.
Consider the disease distribution F (·; a). If it is at a screening age, i.e. if a ∈ As ,
it undergoes screening. The probability of attending was patt, therefore the distribution
is divided into two sub-distributions, the attendants and non-attendants, pattF and (1−
patt)F . Each disease state pattF undergoes treatment with the screening sensitivity s
determined by Equation 3.1.4. Therefore the sub-distribution pattF gets further divided
into two sub-sub-distributions, one with positive test results spattF and one with negative
test results (1− s)pattF . Let the matrix T := spattF denote the findings, i.e. the positive
results. The distribution of the findings, i.e. the number of individuals with CIN, CGIN,
both, or one precancer and one infection, are collected and stored in the T -matrix at each
screening. The individuals that test positive undergo treatment, where the treatment is
defined for every entry T with the treatment function
(3.12)
(T T )(x, y) =

T (x, y) + T (CIN, y), if x = R and y 6= I and y 6= CGIN
T (x, y) + T (x,CGIN), if y = R and x 6= I and x 6= CIN
T (x, y) + T (CIN,CGIN)
+ T (I, CGIN) + T (CIN, I), if y = R and x = R
0, if x = CIN or y = CGIN
T (x, y), otherwise
where infections also get treated when a CIN or CGIN neoplasia is treated. Note that
the treatment function does not affect the number of individuals in total. The treated
T T -matrix is stored at every screening age. After treatment the population is updated
and the subpopulations summed to the screened population
Fscreened = T T + (1− s)pattF + (1− patt)F.
With this screening scheme implemented in the progression model we can collect the
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number of infected at each time step, the number of cancers at each time step, how many
CIN- and CGIN-findings there are at each screening age and we get a picture of how the
cohort is distributed on the states as a function of time.
3.2 Indicators
The indicators, or the interesting numbers to study in our model computations, was
the number of cancers during a lifetime, the cancer prevalence, as well as the number of
findings in screening during a lifetime of a cohort. In the results of one cohort of women we
monitored the lifetime number of adenocarcinomas (ADC). We also studied the neoplasia
findings in screenings and summed them up from all screening rounds during the lifetime
of the population cohort. We studied the lifetime number of squamous neoplasms (CIN)
found in screening rounds, the lifetime number of age-specific glandular neoplasms (CGIN)
found in screening rounds and the lifetime number of findings where both neoplasms were
detected, (CIN,CGIN). In addition to these we studied the lifetime number of findings
with a neoplasia of one type and an infection of the other type, that is (CIN, IADC) and
(ISCC,CGIN). The number of squamous cell carcinomas and adenocarcinomas can be
used to mirror the reality, while studying (CIN, IADC) and (ISCC,CGIN) has important
theoretical value. The types of infections present in a neoplasia are usually not identified
in clinical practice but are crucial to the possible adenocarcinoma increase. The number
of (CIN, IADC) that would be identified through screening would diminish the threat of
adenocarcinoma, but with vaccination this is not the case anymore.
The results are presented with respect to the indicators with cohorts of 100 000 women.
The results consist of prevalences of squamous cell carcinomas, adenocarcinomas, cases
with both cancers present, findings in screening rounds and findings with infection of
the other HPV-type. Note that the number of squamous cell carcinomas, denoted by
SCC, is the sum of all squamous cell carcinomas, including the ones with adenocarcinoma
and HPVADC infections present too. The same applies to adenocarcinomas, the number of
ADC include the cases co-infected with squamous cell carcinomas and HPVSCC infections.
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3.3 Parameters and scenarios
In subsection 3.1.1 we presented the model states and rates between states. Table 3.2
presents the base case values for the model parameters (Table 3.1). These rates are
usually assumed fixed and therefore referred to as parameters. The values in Table 3.2
are reference values, which means that if nothing else is mentioned, these values are the
ones used in computations.
When deciding which parameter values to use as reference values in our model, the
decision was made with two criteria in mind. One was to do the computations with
common "model parameter values", used in e.g. [8]. The other was to check if these are
in line with literature parameters and adjust them so that they are close to real biological
values. Finding which values correspond to reality is challenging and Insinga et al. [28]
reviewed literature to gather parameters used in HPV models. We used this literature
review in addition to parameter estimation from [29] as a guideline for the parameters in
this model.
We executed the analysis with six different populations. The populations were divided
according to three different screening programs and two different levels of sexual activity
(Table 3.3). The screening programs were intensive screening, standard screening and no
screening, while the levels of sexual activity were categorized into average sexual activity
and high sexual activity (higher than the average). These were chosen so that we can
evaluate which consequences screening and vaccination have on adenocarcinomas under
different conditions. The population with standard screening and average sexual activity
was designed to resemble a general population in the western world and the population
with intensive screening and average sexual activity to resemble the situation in Fin-
land, where screening is more intensive due to opportunistic screening. The population
with high sexual activity is a high-risk population with higher force of infection for both
HPVSCC and HPVADC, and was analyzed with different screening scenarios. To study the
effects of vaccination, we computed the same six scenarios in Table 3.3 with vaccination
as well as the difference between vaccination and no vaccination for each population.
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Parameter Symbol Value
Natural history [1/year]
ProgressionHPVSCC piI,SCC 0.1
Progression HPVADC piI,ADC 0.1
Symptom HPVSCC piCIN 0.02
Symptom HPVSCC piCGIN 0.02
Clearance from ISCC ηI,SCC 0.6
Clearance from IADC ηI,ADC 0.6
Clearance from CIN ηCIN 0.1
Clearance from CGIN ηCGIN 0.1
Force of infection
Maximum value HPVSCC [1/year] KSCC 0.12
Maximum value HPVADC [1/year] KADC 0.04
Maximal age [year] aM 22
Tail HPVSCC [year] θSCC 4
Tail HPVADC [year] θADC 2
Screening
Screening sensitivity HPVSCC sSCC 0.9
Screening sensitivity HPVADC sADC 0.1
Intensive screening [ages] InS (21, 24, 27 . . . 60)
Standard screening [ages] StS (30, 35, 40 . . . 60)
Attendance probability patt 0.8
Time progression
Model enter age a0 10
Model exit age an 70
Time step ∆t 1/52
Table 3.2: Base case parameter values.
To evaluate how the number of adenocarcinomas changed as a function of input pa-
rameter values and interventions, we performed a sensitivity analysis. We wished to know
if there were certain conditions or virus type characteristics that amplified these changes
in adenocarcinoma prevalence and if there are some parameters that have a greater impact
than others.
To understand how screening affects the number of cancers and neoplasms the screen-
ing sensitivities sSCC and sADC were analyzed. To assess how the sexual behavior alters
the number of cancers and neoplasms, we analyzed the force of infection input parameters
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Sexual behavior
Average Active
Intensive screening
Standard screening
No screening
Table 3.3: Populations.
KSCC and KADC . To understand how natural history parameters contribute we analyzed
the recovery parameters ηISCC , ηIADC , ηCIN and ηCGIN . These eight parameters were
chosen as a starting point for the analysis.
The sensitivity analysis was conducted by computing the lifetime number of adeno-
carcinomas as a function of the parameters stated above, without vaccinating the popu-
lation. Then we did the same thing, but with vaccination, and compared compared the
two outcomes. To determine if the two outcomes with and without vaccination differed
significantly from each other, we defined a significance level. Suppose that the lifetime
number of adenocarcinomas depend on a parameter value. If this lifetime number dif-
fers when comparing vaccination and no vaccination, we state that the parameter has an
impact. To know which parameter value result in a difference between adenocarcinomas
in a vaccinated and a non-vaccinated population, we first computed how much the max-
imal relative change in adenocarcinomas is without vaccination. Then we computed the
same thing with vaccination and the difference between the relative changes determines
if the parameter has an impact on the vaccination-induced adenocarcinoma increase. We
used the relative difference instead of the absolute difference because the comparability
between the parameters was clearer with the relative difference.
In addition to computing the difference in the adenocarcinoma increase, we also de-
termined which specific parameter value resulted in the maximal relative difference. This
was done with the purpose to get a theoretical limit to how much parameters can affect
the number of adenocarcinomas.
To analyze how adenocarcinomas depend on a parameter, we defined the range where
we perturb the parameter. Denote the number of adenocarcinomas by n, and denote a
parameter by θ , and let θ vary on an interval Θ. Here Θ is an interval chosen so, that
the parameter value is biologically relevant, we do not include extremely high rates that
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would be impossible to have in a real life setting. Hence we do not have to take into
account the question of convergence of cancer cases when θ goes to infinity.
Denote the vaccination status with v0 for a non-vaccinated cohort and with v1 for
a vaccinated cohort. The maximal relative change of cancer cases as a function of the
rate-parameter θ is given by
(3.13) dvi =
maxθ∈Θ{n(θ)} −minθ∈Θ{n(θ)}
maxθ∈Θ{n(θ)} , i = 0, 1,
and comparing the dv1 of the vaccinated cohort with the non-vaccinated dv0 cohort gives
and indication whether the parameter has an impact on the adenocarcinomas. In other
words, if the dv0 and dv1 are approximately the same, the vaccine has the same effect on
the number of cancers.
To know if the parameters actually have an impact on the adenocarcinoma prevalence,
we defined a significance level. If the difference of adenocarcinomas as function of the
parameter in a vaccinated population and a non-vaccinated population was greater than
the significance level, we included the parameter into our analysis. Therefore we set that
if the compared difference is above a significance level,
(3.14) dc = |dv0 − dv1| ≥ 0.025,
we state that the parameter has an impact. For the parameters above the significance
level, we compute the parameter value with maximal impact. We define the parameter
value θm to yield the maximal difference in adenocarcinoma cases by
(3.15) θm = arg max
θ∈Θ
{|nv1(θ)− nv0(θ)|}.
3.4 Practical computations and model validation
The age-cohort model and the progression in time were computed by writing MATLAB
scripts including the time progression with screening and vaccination schemes. Model
validation of the program scripts was done by checking at each time step that the indi-
viduals in all compartments summed up to the whole population size. We also checked
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that the columns of the natural history matrix summed to one at different times. For an
actual example of a screening round and time progression step, see Appendix C.
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Chapter 4
Results
In this chapter we illustrate the outcomes with the basic model properties. We present
the prevalence distributions with and without screening and the findings from screening.
We present the different populations described in Table 3.3 and their cancer prevalences
without vaccination. After this the prevalences with vaccination are presented and we
show how they are affected by vaccination. Lastly we introduce the parameters that we
chose to variate in the sensitivity analysis, and the results from the parameter variations.
4.1 Pre-vaccination
In this section we present the results for populations without vaccination. These results
are needed and used in the next section for comparison with the results from vaccinating
the populations.
4.1.1 Prevalences
To illustrate what kind of distributions on the disease states the model produced, we
computed prevalence distributions for an age cohort without screening and with the base
case parameters in Table 3.2 before analyzing impacts of vaccination. With the base case
parameters and without screening 1, 1% developed adenocarcinoma during their lifetime
and 2, 2% developed squamous cell carcinoma. Most of the cancers developed between
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the ages 20 and 45. The number of individuals in CIN states increase up to age 25, after
which they decrease. During the lifetime of the cohort 8, 2% remained susceptible and
89, 4% recovered and acquired immunity for HPVSCC, while 53, 9% remained susceptible
and 44, 7% became recovered and immune to HPVADC, see Figure 4.1. The maximal
prevalence for HPVSCC infection was 9, 9% (age 21) and for HPVADC 4, 7% (age 24),
which also is illustrated in Figure 4.1.
Figure 4.1: Prevalences with baseline parameters and without screening. The first row is HPVSCC
prevalence and the second row is HPVADC prevalence.
With base case parameters and standard screening the model resulted in 1, 0% de-
veloped adenocarcinomas and 1, 4% developed squamous cell carcinomas which is 8, 3%
and 36, 3% less than without screening, respectively. While most people got infected with
HPVSCC, 90, 3% recovered, see Figure 4.2. The infection peak prevalence is 9, 8% for
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HPVSCC and declines after the age of 21. Of the population cohort only 8, 2% completely
avoided the infection of HPVSCC. The decrease in adenocarcinomas is enhanced by stan-
dard screening starting at age 30. Over half of the population remains susceptible to
HPVADC during their lifetime. The infection peak prevalence for HPVADC is around age
24 at 4, 7%. The effects of screening can be seen in Figure 4.2 as drops in CIN and CGIN
numbers. The screening sensitivity is smaller for HPVADC alone, so the drops in CGIN
cases at screening ages can be seen but they are not as striking as for CIN, as shown in
Figure 4.2.
Figure 4.2: Prevalences with baseline parameters and standard screening. The first row is HPVSCC
prevalence and the second row is HPVADC prevalence.
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4.1.2 Screening findings
Screening was conducted with two different screening programs. Standard screening
means that the cohort is screened every fifth year between age 30 and 60, while intensive
screening means that the cohort is screened every third year between 21 and 60. We also
computed results without screening.
In screening the number of precancerous cases, CIN and CGIN-cases, were collected
and the number of findings in screening varied with the screening intervals. Consider a
cohort of 100 000 women. With standard screening the number of CIN findings were over
3129 at the first screening round at age 30, while the second screening at age 35 produced
974 CIN findings and the number of findings decreased from that age at each screening
(Figure 4.3). The lifetime number of CIN findings from all screening rounds was 4783.
The number of CGIN findings were also highest at age 30 with 256 findings and decreased
at each screening round after the first. The lifetime number of CGIN findings from all
screening rounds was 600. The number of cancers were not detected in screening, because
of the model assumption that if a precancerous lesion progressed to cancer, the cancers
would be found by their symptoms and not by the screening program.
The findings, which are crucial to the detection and treatment of adenocarcinoma,
are the ones with both CIN and CGIN states present. With standard screening the first
screening round at age 30 revealed 75 precancerous findings with both CIN and CGIN
present after which the co-findings rapidly declined. The lifetime number of findings in a
cohort of 100 000 women with both types present from all screening rounds was 97 with
standard screening.
With standard screening the number of findings with CIN and IADC present was 66 at
the first screening at age 30, 8 at age 35 and 1 at age 40. The detailed figures from these
can be found in Appendix A in tables A.3 and A.4.
The number of lifetime squamous cell carcinomas with standard screening was 1379,
while the number of lifetime adenocarcinomas was 968.
With intensive screening of the cohort of 100 000 women the number of CIN findings
were 2907 at age 21, and decreased with every screening round after that. The lifetime
number of CIN findings was 8953. The number of CGIN findings was not decreasing from
the first screening round, but was at its highest at age 27 with 206 findings, (Figure 4.3),
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where after the number of findings in each screening round declines. The lifetime number
of CGIN findings with intensive screening was 1247. The findings with both CIN and
CGIN present declined after age 23 with 42 findings, and the lifetime number of findings
with both types present was 154.
Even though the number of findings at the first screening round was higher with
standard screening compared to intensive, the total number of findings is higher with
intensive screening. This means that the more we screen, the more we find. Recall that
in this model the cancers in the late stages (SCC and ADC) are not found in screening,
but are found by theirs symptoms outside the screening program. Therefore the cancer
findings are not reported at screenings, but in the next section.
Figure 4.3: Number of CIN-findings and CGIN-findings at each screening age. Left: Standard screening.
Right: Intensive screening.
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4.1.3 Baselines for different screening scenarios
We computed the model outcomes with cohorts from different populations without vac-
cination, to know what to compare with when vaccinating. The populations were the
average sexual activity level population with intensive, standard and no screening and
the high sexual activity population with intensive, standard and no screening, as pre-
sented in section 3.3. The cohort size is 100 000 throughout the chapter.
In the population with high sexual activity the number of adenocarcinomas were the
highest. In a birth cohort in this group of 100 000 women, no screening led to 2155
adenocarcinomas during their lifetime (Table 4.2). Standard screening in the population
with high sexual activity a led to 1994 adenocarcinomas, while intensive screening led to
1722 adenocarcinoma cases during the lifetime. The number of squamous cell carcinomas
was also high without screening with 2376 cases. Standard and intensive screening led to
1882 and 1000 cases of squamous cell carcinoma respectively.
Average sexual activity resulted in less adenocarcinomas and squamous cell carcino-
mas compared to the population with high sexual activity (Table 4.1). In a cohort of 100
000 women the number of adenocarcinomas was 1067 without screening, 968 with stan-
dard screening and 857 with intensive screening. The respective numbers for squamous
cell carcinomas was 2162 without screening, 1379 with standard screening and 683 with
intensive screening.
No screening resulted, naturally, in no precancerous findings. Intensive screening
compared to standard screening led to more findings of both CIN and CGIN for both
the high and average sexual activity levels (Table 4.2 and Table 4.2).
Sexual activity: average
SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Intensive screening 683 857 6 8953 1247 154 305 39
Standard screening 1379 968 14 4784 600 97 76 8
No screening 2162 1067 23 0 0 0 0 0
Table 4.1: Average sexual activity, different screenings. The SCC and ADC are numbers of squamous
cell carcinomas and adenocarcinomas in a lifetime, CIN and CGIN are neoplasia findings, and ISCC and
IADC are infected but not neoplastic states discovered with neoplastic findings. Cohort size: 100 000.
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Sexual activity: high
SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Intensive screening 1000 1722 18 8281 2515 372 863 41
Standard screening 1882 1994 38 2991 984 132 62 1
No screening 2376 2155 51 0 0 0 0 0
Table 4.2: Sexually active population, different screenings. The SCC and ADC are numbers of squamous
cell carcinomas and adenocarcinomas in a lifetime, CIN and CGIN are neoplasia findings, and ISCC and
IADC are infected but not neoplastic states discovered with neoplastic findings. Cohort size: 100 000.
4.2 Post-vaccination
In this section we present the results for vaccinated populations. We computed the results
with the same inputs for the same populations as in the previous chapter but with vacci-
nation of the cohort. Thus we could compare the results of identical populations where
vaccination was the only difference. The vaccine offers full protection against infections
of HPVSCC and no protection against HPVADC. The results in this section are presented
in cohorts with 100 000 women.
For the cohort with average sexual activity the number of adenocarcinomas increased
with vaccination with both intensive and standard screening (Table 4.3). The increase in
adenocarcinomas was positive with 25 cases (2, 9%) with intensive screening comparing
vaccination with no vaccination. With intensive screening the number of precancerous
CGIN findings decreased by 108 cases (8,7 %) with vaccination and the number of co-
infected CIN- and IADC-findings decreased with 305 cases (100 %) with vaccination. The
number of squamous cell carcinomas decreased from 683 to 0 (100 %) with vaccination
and the number of CIN-findings decreased from 8953 to 0 (100 %), as all the precancerous
lesions and cancers associated with HPVSCC are eliminated as a result of vaccination.
Standard screening of the cohort with average sexual activity the vaccination increased
the number of adenocarcinomas with 15 cases (1,5 %) (Table 4.3), wich is still a positive
increase but less than with intensive screening. The total number of adenocarcinomas (983
with vaccination) is, however, higher than with intensive screening (882 with vaccination).
The precancerous CGIN-findings decreased by 78 cases (13,0 %). The co-infected CIN-
and IADC-findings decreased with 76 (100 %). There was also a anticipated decrease of
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1379 (100 %) squamous cell carcinoma cancers and a decrease of 4784 CIN-findings (100
%) with standard screening.
To compare the previous results to the situation without screening, we found that no
screening of an average sexual activity level population led to 1067 cases of adenocarci-
noma with and without vaccination (Table 4.3), there was no increase in adenocarcinoma
since there was no screening and the vaccination alone does not result in a change in
adenocarcinoma. The vaccination eliminated the squamous cell carcinoma entirely, from
2162 to 0 (100 %). No screening led naturally to no findings.
If we would not only start vaccinating a population with average sexual activity, but
also decrease the screening frequencies from intensive to standard screening the increase
of adenocarcinomas would be 126 cases (14,7 %) which is significantly higher than with
only vaccination. If we would decrease screening from intensive to no screening and start
vaccinating, the adenocarcinoma increase would be even greater with 210 cases (24,5
%) more. Both the vaccination and the screening frequency affected these numbers, the
increase is not only a result of vaccination.
Vaccination had an impact on the adenocarcinoma increase in the population with
high sexual activity. For the population with high sexual activity level and intensive
screening the number of adenocarcinomas increased with 63 cases (3,7 %) with vaccination
(Table 4.4) which is a greater increase compared to the average sexual activity level.
Vaccination of the population with intensive screening led to an decrease of 258 (10,3 %)
precancerous CGIN-findings. The co-infected CIN and IADC-findings decreased from 863
to 0 (100 %) with vaccination. Vaccination led also to a decrease of 1000 squamous cell
carcinomas (100 %) and a decrease of 8281 CIN findings (100 %).
Standard screening and vaccination of a population with high sexual activity led to
an adenocarcinoma increase of 19 cases (1,0 %), less than with intensive screening. We
observed a decrease of 107 (10,8 %) precancerous CGIN-findings (Table 4.4), a relative
decrease quite close to the one with intensive screening. A decrease of 62 cases (100 %)
for the co-infected CIN and IADC-findings was also observed with vaccination. With full
vaccine coverage the squamous cell carcinomas were completely eliminated (from 1882 to
0, 100 % decrease) and the same applied naturally for the CIN findings.
With no screening the vaccination had no impact on the number of adenocarcinomas
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of the population with high sexual activity (Table 4.4). Without screening there are no
effects of vaccination against HPVSCC on adenocarcinoma. The squamous cell carcino-
mas dropped from 2376 to 0 (100 %) and there were no CIN or CGIN findings without
screening.
If vaccination would be combined with a decrease in screening frequencies, the ade-
nocarcinoma increase would be more prominent. We studied a cohort with high sexual
activity, vaccination and intensive screening and compared this to screening the cohort
with standard screening. We got an adenocarcinoma increase of 291 cases (16,9 %) and
switching to no screening would give a total increase of 433 (25,1 %) new adenocarcinomas
compared to the situation without vaccination and with intensive screening.
When comparing the number of adenocarcinomas with and without vaccination (Ta-
ble 4.3 and Table 4.4) we see that the sexual activity and the screening frequency both
have an impact on the number of cancers. The sexually active population with intensive
and standard screening develops 3,7 % and 1,0 % more adenocarcinomas, respectively,
when vaccinating, while the population with average sexual activity and intensive and
standard screening develops 2,9 % and 1,4 %, respectively, more adenocarcinomas with
vaccination.
4.3 Sensitivity analysis
4.3.1 Choosing parameters to variate
To understand which parameters have an impact on adenocarcinomas, we followed the
procedure described by Equations 3.13, 3.14 and 3.15. We computed the dc-values with
standard and intensive screening, and we observed that the screening affected the dc-value.
All dc-values were higher with intensive screening compared to standard screening, which
means that the difference in adenocarcinomas between vaccinating and not vaccinating
is greater with intensive screening. Parameters relating to HPVADC had dc-values below
0,025 and were excluded from the significant parameters. Computing with Equation 3.14,
the results with dc ≥ 0, 025 are presented in Table 4.5. As long as one of the dc-values
was above the significance level, the parameter was considered meaningful.
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dc
Parameter Symbol Standard screening Intensive screening
Screening sensitivity HPVSCC sSCC 0.5% 3.08%
Clearance from IADC ηI,ADC 1.25% 6.37%
Clearance from CIN ηCIN 1.86% 4.88%
Maximum value HPVADC KADC 0.4% 2.93%
Table 4.5: Assessment of parameters, where dc-values are computed with equation 3.14
4.3.2 Parameter variation
To analyze the impact that the parameters, chosen above, had on the adenocarcinoma
prevalence, the adenocarcinomas were plotted as functions of the parameter values. This
was done by keeping all other parameters according to Table 3.2 and varying one param-
eter in a suitable interval. The results are presented in figure Figure 4.4 and Figure 4.5
where the cohorts are with and without vaccination. The cancer cases on the vertical axis
are all adenocarcinoma cases, because it is in these we expect to observe type replacement.
The same plots for squamous cell carcinomas are found in Appendix A.
The plots on the right hand side in figure Figure 4.4 and Figure 4.5 show little dif-
ference between vaccinated and non-vaccinated cohorts. That is because the HPVADC
parameters relate directly to the HPVADC cancers. The reason why the lines do not co-
incide completely, is because ADC also contains the co-cancer (SCC,ADC) and without
vaccination some HPVADC infections are treated with the CIN findings. This was checked
through doing the same computations but without screening, in which case the number
of cancers coincided between the vaccinated and non-vaccinated cohorts.
The screening sensitivity parameter for squamous cell carcinomas affected the number
of adenocarcinomas. In the upper left plot of Figure 4.4 the lifetime number of adenocar-
cinomas decrease with increased screening sensitivity for HPVSCC, while for a vaccinated
cohort the number of cancer cases remains constant. This implies that a better the
sensitivity for screening squamous cell carcinomas leads to less cases of adenocarcinoma
since the screening detects some of the CGIN:s too. The difference in adenocarcinoma
prevalence in vaccinated and not vaccinated populations is largest when the screening
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for HPVSCC has a perfect sensitivity, sSCC = 1. With this perfect screening sensitivity
the impact is maximal and the adenocarcinomas increase with 15,8 cases (1, 6%) when
vaccinating the standard population and with 26,1 cases (3, 1%) when vaccinating the
intensive-screening population, see Table 4.6.
Varying the maximum of the force of infection parameter KSCC also had an impact on
the adenocarcinoma prevalence. The lifetime number of adenocarcinomas as a function
of the force of infection maximum KSCC shows an interesting property in Figure 4.4,
where the adenocarcinoma lifetime incidence is first decreasing and then increasing as a
function of KSCC . There are two main reasons for this behavior, firstly the number of
ADC including the co-cancers (SCC,ADC) results in the non-monotonous behavior, since
the number of SCC, and hence also (SCC,ADC), increase as a function of KSCC . When
KSCC and KADC coincide, the flows into the CIN and CGIN states are approximately
alike, and a large fraction of these are treated because of finding a CIN. When the force of
infection maximum for HPVSCC is higher compared to HPVADC, the flow to CIN is greater
than to CGIN and when treatment is started because of screenings the part in CGIN but
not yet in CIN is treated and found, which allows them to still develop adenocarcinoma
but the chance of finding these in screening are small. This property is related to the age-
dependency of the force of infection intertwined with screening also being age-determined.
The maximal difference in adenocarcinomas between a vaccinated and non-vaccinated
cohort is when KSCC = 0.1. This limit value led to an increase of 14,3 cases (1, 5%) with
standard screening and 23,9 cases (2, 8%) with intensive screening. Hence the impact of
the force of infection maximum is less than the impact of the screening sensitivity, see
Table 4.7.
The clearance rates ηI,SCC and ηCIN had the largest effect on the adenocarcinoma
prevalence. The difference in adenocarcinoma prevalence between a fully vaccinated pop-
ulation and a non-vaccinated population is largest when the clearance rates are at zero,
as seen in Figure 4.5. The limit value that led to the greatest increase in adenocarci-
nomas was ηI,SCC = 0. Standard screening and ηI,SCC = 0 led to an increase of 105,7
cases (12, 0%) in adenocarcinoma prevalence, while intensive screening led to an increase
of 147,4 cases (20, 1%), see Table 4.8. Clearance from CIN-state had also an impact,
ηCIN = 0 and standard screening increased the adenocarcinoma prevalence with 32,7
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Figure 4.4: The lifetime number of adenocarcinomas per 100 000 women with standard screening and
varying value for (A) screening sensitivity sSCC , (B) screening sensitivity sADC , (C) force of infection
maximum KSCC and (D) force of infection maximum KADC .
cases (3, 4%) while intensive screening led to an increase of 34,2 cases (4, 0%).
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Figure 4.5: The lifetime number of adenocarcinomas per 100 000 women with standard screening and
varying value for (A) recovery rate ηI,SCC , (B) recovery rate ηI,ADC , (C) recovery rate ηCIN and (D)
recovery rate ηCGIN .
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SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Standard screening 1333,7 967,3 13,1 5054,4 606,2 103,4 83,0 7,7
Standard screening with vaccination 0,0 983,1 0,0 0,0 522,4 0,0 0,0 0,0
change -1333,7 15,8 -13,1 -5054,4 -83,8 -103,4 -83,0 -7,7
change (%) -100,0 % 1,6 % -100,0 % -100,0 % -13,8 % -100,0 % -100,0 % -100,0 %
Intensive screening 625,0 855,6 5,5 9303,2 1250,1 156,8 321,9 39,1
Intensive screening with vaccination 0,0 881,7 0,0 0,0 1138,9 0,0 0,0 0,0
change -625,0 26,1 -5,5 -9303,2 -111,3 -156,8 -321,9 -39,1
change (%) -100,0 % 3,1 % -100,0 % -100,0 % -8,9 % -100,0 % -100,0 % -100,0 %
Table 4.6: Results for standard and intensive screening with sSCC = 1.
SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Standard screening 1276,7 968,8 12,6 4774,5 598,6 95,0 73,5 8,5
Standard screening with vaccination 0,0 983,1 0,0 0,0 522,4 0,0 0,0 0,0
change -1276,7 14,3 -12,6 -4774,5 -76,2 -95,0 -73,5 -8,5
change (%) -100,0 % 1,5 % -100,0 % -100,0 % -12,7 % -100,0 % -100,0 % -100,0 %
Intensive screening 637,8 857,8 5,7 8605,2 1242,6 147,2 281,7 39,0
Intensive screening with vaccination 0,0 881,7 0,0 0,0 1138,9 0,0 0,0 0,0
change -637,8 23,9 -5,7 -8605,2 -103,7 -147,2 -281,7 -39,0
change (%) -100,0 % 2,8 % -100,0 % -100,0 % -8,3 % -100,0 % -100,0 % -100,0 %
Table 4.7: Results for standard and intensive screening with KSCC = 0, 1.
SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Standard screening 7323,0 877,4 72,3 45061,2 1094,7 711,5 493,3 116,2
Standard screening with vaccination 0,0 983,1 0,0 0,0 522,4 0,0 0,0 0,0
change -7323,0 105,7 -72,3 -45061,2 -572,3 -711,5 -493,3 -116,2
change (%) -100,0 % 12,0 % -100,0 % -100,0 % -52,3 % -100,0 % -100,0 % -100,0 %
Intensive screening 4092,3 734,2 36,4 64305,8 1833,9 966,6 1374,0 316,3
Intensive screening with vaccination 0,0 881,7 0,0 0,0 1138,9 0,0 0,0 0,0
change -4092,3 147,4 -36,4 -64305,8 -695,1 -966,6 -1374,0 -316,3
change (%) -100,0 % 20,1 % -100,0 % -100,0 % -37,9 % -100,0 % -100,0 % -100,0 %
Table 4.8: Results for standard and intensive screening with ηI,SCC = 0.
SCC ADC (SCC,ADC) CIN CGIN (CIN,CGIN) (CIN, IADC) (ISCC , CGIN)
Standard screening 2320,7 950,4 22,9 10695,5 696,5 217,0 167,4 7,7
Standard screening with vaccination 0,0 983,1 0,0 0,0 522,4 0,0 0,0 0,0
change -2320,7 32,7 -22,9 -10695,5 -174,0 -217,0 -167,4 -7,7
change (%) -100,0 % 3,4 % -100,0 % -100,0 % -25,0 % -100,0 % -100,0 % -100,0 %
Intensive screening 880,9 847,5 7,8 12139,2 1285,6 208,7 412,1 39,1
Intensive screening with vaccination 0,0 881,7 0,0 0,0 1138,9 0,0 0,0 0,0
change -880,9 34,2 -7,8 -12139,2 -146,8 -208,7 -412,1 -39,1
change (%) -100,0 % 4,0 % -100,0 % -100,0 % -11,4 % -100,0 % -100,0 % -100,0 %
Table 4.9: Results for standard and intensive screening with ηCIN = 0.
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Chapter 5
Discussion
The purpose of this study was to determine if vaccinating a population in a screening pro-
gram increases the number of adenocarcinomas with a vaccine that only protects against
viruses that are found in squamous cell carcinoma. We modeled the mechanism with a
deterministic two-type HPV model. We developed a computational model with screening
and vaccination, and computed results for six different cohorts of women. We found that
the vaccination-induced increase in adenocarcinoma prevalence was positive but small
and that sexual activity and screening intervals had an impact on the adenocarcinoma
increase.
Our results indicate that there is an increase in adenocarcinomas in all the model-
populations. This increase is however minor compared to the decrease in squamous cell
carcinomas due to vaccination, and the combined number of cancers is smaller due to
vaccination in all populations. Based on our results the increase in adenocarcinomas is
dependent of the screening frequency. In a population with intensive screening and vac-
cination, the relative increase in adenocarcinomas was higher than in a population with
standard screening and vaccination. We observed that when there was an increase in
adenocarcinomas as a result of vaccination, there was also a reduction in CGIN findings.
This implies that there is a relationship between the number of CGIN findings and the
adenocarcinoma prevalence. With total vaccination coverage the CIN-findings were re-
duced to zero and therefore also the findings with co-infections of CIN and CGIN as well
as CIN and IADC were reduced to zero, so that these were not found in screening. Our
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results showed that if there was an increase in adenocarcinoma, there was also a reduc-
tion in precancerous CGIN findings and combined CIN- and IADC-findings. This implies
that there is a relationship between the increase in adenocarcinomas and the number
of HPVADC infections that are not found in screening when vaccinating. Based on our
results, the vaccination-induced adenocarcinoma increase was greatest when vaccination
was combined with a reduction of screening frequency.
In the screening findings that the model produced, we observed that the number
of co-infections, where both strains had proceeded to precancerous stages, was higher
with intensive screening compared to standard screening. Since the combined CIN- and
HPVADC-infections are a crucial aspect, fewer co-infections detected in screenings could
lead to a higher number of adenocarcinomas in a screened and vaccinated population. In
the model with the base case parameters most infections had already progressed to cancer
before the start of screening when we studied standard screening. Therefore the intensive
screening might present a more realistic outcome.
There are additional circumstances that enhance and affect the adenocarcinoma in-
crease. A low recovery rate for the states precessing squamous cell carcinoma had the
greatest impacts on the adenocarcinoma increase. The chance that the recovery rate for
HPV 16 would be zero is very small, both for infection and CIN. The probability that
an infection clears by itself is high, around 80% of infections clear spontaneously. Hence
the increase of adenocarcinomas with zero recovery from precancerous squamous cell car-
cinoma can be considered to have mainly theoretical value. The sensitivity of screening
tests is high [30] so the impact of vaccination and screening increasing the number of
adenocarcinomas is possible and probable and one could expect an increase as predicted
in the results. The force of infection relates to the type of population or cohort that we
model, and in a population with higher sexual activity, the adenocarcinoma increase is
somewhat more prominent compared to an average population when both are participat-
ing in intensive screening.
Taking our results into consideration, a possibility of adenocarcinoma increase as a
result of screening and vaccination should be taken into account when assessing vaccina-
tion and screening programs. The results imply that the number of cancers prevented by
vaccines is at least fourfold and in most cases over tenfold the number of adenocarcino-
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mas caused indirectly. Therefore the increase in adenocarcinomas does not pose a strong
argument against vaccinations.
As with most modeling studies, simplifying parameter choices and model choices were
made for the sake of clarity and computability and may be a limiting factor. The force of
infection could be modeled more accurately with a contact model to get a more reality-like
situation, but this was disregarded on purpose because of the focus on the development
of cancers instead of the transmission dynamics. Some of the base case parameters can
be unrealistic in a real life setting, despite our attempts to adjust them to parameters
established in literature. This is certainly true since different communities have differ-
ent structures, which affect the parameters as well. Our model-HPV-types are also not
completely identical to HPV 16 and 45. In reality HPV 16 causes some adenocarcinoma
and HPV 45 some squamous cell carcinoma, so the numbers in the results are not equiv-
alent to HPV 16 and 45, but form a guideline. Screening aside, the virus types were
assumed independent of each other, which is a plausible assumption [15]. The natural
history parameters were assumed independent of age, which is an assumption supported
by literature [29].
Considering population-level dynamics instead of individual-level dynamics is common
when modeling biology with mathematics. A deterministic model is a good choice for
accurate and fast computations for one or a few virus types and large populations, but
becomes rapidly too complex with many virus strains. A stochastic model on the other
hand is efficient when dealing with many strains, or with few individuals. We chose a
deterministic model, since the number of disease states was manageable for a deterministic
one. For the sake of clarity and computability our model is a simplification of a real life
scenario.
The results in this thesis should be assessed as an indicator of what could happen
in a real life situation. Reality is of course far more complex than what is described
in the model we developed, but in this study we found limiting bounds for how much
adenocarcinomas could increase, which means that in real life the situation should not be
worse than these results imply.
Further analysis could be conducted by focusing on adjusting the parameters even
more close to the reality. This could give an even more realistic prediction of the adeno-
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carcinoma prevalence in women. That being said, the new nonavalent vaccine protects
against all the virus types in this study and therefore future generations vaccinated with
the nonavalent vaccine do not have to be concerned with the screening- and vaccination-
induced adenocarcinoma increase. In addition to this, the bivalent vaccine provides cross
protection against HPV 45, which is highly represented in adenocarcinomas whereas the
quadrivalent vaccine, modeled in this thesis, does not protect against HPV 45 to the same
extent.
Even though the quadrivalent vaccine has been in use for a decade the mechanisms of
adenocarcinoma increase have remained unclear. This study proposes insight in what to
expect in the following years of screening. Based on our results, vaccinating a screened
population increased the adenocarcinoma prevalence in all our proposed types of popula-
tions, although the increase was minor.
In conclusion we predict a small increase for adenocarcinomas associated with the
HPV types which the vaccine does not protect against. An increase in adenocarcinomas
due to the effects of screening combined with vaccination is likely. How clearly this
minor increase will be observed is would be the topic of another study, but it can be an
important aspect to bear in mind that a woman vaccinated against HPV can be developing
an adenocarcinoma tumor. Our study has shown the importance of taking into account
the risk of adenocarcinomas in women vaccinated against HPV.
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Figure A.1: The lifetime number of squamous cell carcinomas per 100 000 women with standard screening.
First row: The number of squamous cell carcinomas during a lifetime as a function of recovery rate
from infection. Second row: The number of squamous cell carcinomas during a lifetime as a function
of the recovery rate from the precancerous state.
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Figure A.2: The lifetime number of squamous cell carcinomas per 100 000 women with standard screen-
ing. First row: The number of squamous cell carcinomas during a lifetime as a function of screening
sensitivity. Second row: The number of squamous cell carcinomas during a lifetime as a function of the
force of infection maximum K. Screening: standard, cohort size: 100 000.
53
Figure A.3: Findings from standard screening. Cohort size: 100 000.
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Figure A.4: Findings from intensive screening. Cohort size: 100 000.
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Appendix B
Markov chains
Markov processes are powerful tools in modelling random processes in time. The idea is
simple, any future state of a random process is determined only by the current state and
is unaffected by the past. A process like this is called a Markov process. If the process can
attain only a finite number of states, it is called a Markov chain. The formal definitions
are presented below.
Let I be a countable set, and let the elements i in the state space I be states. Now
λ = (λi : i ∈ I) is a measure of I if the measure is finite 0 ≤ λi ≤ ∞ for all i ∈ I.
Definition B.1. The measure λ is a distribution if
∑
i∈I
λi = 1.
Recall that a random variableX taking values in I is a functionX : Ω→ I in a probability
space (Ω,F ,P), and λ defines a distribution when we let
λi = P(X = i) = P({ω : X(ω) = i}).
A matrix is called a stochastic matrix, or a transition probability matrix if every column
sums to 1. We define P to be a stochastic matrix, in which all entries are non-negative
and the entry pij is the probability of transitioning from state j to state i. Using this
matrix we can define Markov chain.
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Definition B.2. (Xn)n≥0 is a Markov chain with initial distribution λ and a transition
matrix P if
(i) X0 has the distribution λ,
(ii) Xn has distribution (pij : j ∈ I) and is independent of Xn−1, Xn−1, . . . , X0. In other
words, P(Xn+1 = in+1|X0 = i1, . . . , Xn = in) = P(Xn+1 = in+1|Xn = in) = λpinin+1
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Appendix C
Model demonstration and validation:
a screening round and time
progression step
We performed one screening round with a time progression step, in order to demonstrate
the mechanisms behind the simulations. This computation serves also as a model valida-
tion, as we checked that the program gives the same result as this computation done by
hand.
Recall that the distribution between the two types of HPV states is in matrix form
F (t) =

fS,S fS,I fS,CGIN fS,ADC fS,R fS,V
fI,S fI,I fI,CGIN fI,ADC fI,R fI,V
fCIN,S fCIN,I fCIN,CGIN fCIN,ADC fCIN,R fCIN,V
fSCC,S fSCC,I fSCC,CGIN fSCC,ADC fSCC,R fSCC,V
fR,S fR,I fR,CGIN fR,ADC fR,R fR,V
fV,S fV,I fV,CGIN fV,ADC fV,R fV,V

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and suppose that t = 30. Assume that the specific distribution at this age is
F (30) =

0.20 0.01 0.01 0.01 0.10 0
0.01 0.05 0.01 0.01 0.05 0
0.01 0.01 0.01 0.01 0.05 0
0.01 0.01 0.01 0.01 0.01 0
0.15 0.01 0.05 0.01 0.18 0
0 0 0 0 0 0

.
The sensitivity to detect a CIN state is sSCC(CIN) = 0.9 for the type alone, sADC(CGIN) =
0.1 for type alone and therefore s(CIN,CGIN) = 1−(1−sSCC(CIN))(1−sADC(CGIN) =
0.91 for co-infection. The sensitivities are zero for all states, except the CIN- and CGIN-
states, see explanation in subsection 3.1.4.
Suppose that the screening ages are As = {30, 35, . . . , 60}. Since our age is a screening
age we perform a screening where we assume that the probability of attending screening
is patt = 0.8 and the part of the cohort attending screening is therefore pattF (30), while
the part that is not attending is naturally (1−patt)F (30). Among the attenders we detect
precancerous findings
T = spattF (30) =

0 0 0.0008 0 0 0
0 0 0.0008 0 0 0
0.00720 0.00720 0.00728 0.00720 0.036 0
0 0 0.0008 0 0 0
0 0 0.004 0 0 0
0 0 0 0 0 0

.
These findings are stored at every screening round and are referred to as precancerous
findings. They are treated according to the screening scheme and then moved to the
recovered compartment. The treated findings are added to recovered states according
to the treatment function T in Equation 3.12 where (ISCC , CGIN), (CIN, IADC) and
(CIN,CGIN) findings are moved to (R,R), since underlying infection automatically also
gets treated when any infection is treated. This is followed by moving treated (CIN, x) to
(R, x) where x ∈ X\{CIN, I} and equally (y, CGIN) to (y,R) where y ∈ X\{CGIN, I}.
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The detected part of the cohort becomes a treated cohort,
T T =

0 0 0 0 0.0008 0
0 0 0 0 0 0
0 0 0 0 0 0
0 0 0 0 0.0008 0
0.0072 0 0 0.0072 0.0553 0
0 0 0 0 0 0

.
The cohort-part that attended screening but where the sensitivity of the screening test
was not sufficient to detect the precancers, or where the attenders did not have precancers,
is consequently (1− s)pattF (30). The screened cohort is updated by
Fscreened(30) = T T + (1− s)pattF (30) + (1− patt)F (30)
and now we can perturb it by the a time step ∆t = 1/52 (1 week), which is the time step
we use in the simulation.
Assume that the rates and force of infection parameters are
piI,SCC = piI,ADC = 0.3 piCIN = piCGIN = 0.03
ηI,SCC = ηI,ADC = 0.5 ηCIN = ηCGIN = 0.2
KSCC = 0.12 KADC = 0.06
aM = 22 θSCC = θADC = 4
where all rates are expected number of transitions per unit of time, and the time unit is
one year. To ease the computations we form two type-specific rate-matrices, where each
entry q(x, y) is the transition from state y ∈ X to state x ∈ X. The matrix takes the
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form
Qi(t) =

0 0 0 0 0 0
λ(t)i 0 0 0 0 0
0 piI,i 0 0 0 0
0 0 pij 0 0 0
0 ηIi ηj 0 0 0
0 0 0 0 0 0

,
where i = SCC and j = CIN for squamous cell carcinoma HPV and i = ADC and
j = CGIN for adenocarcinoma HPV. Now we can compute the transition probability
matrices NSCC∆t and NADC∆t , using Equation 3.8 and Equation 3.9. The forces of infection
computed at this age with Equation 3.1 are λSCC(30) = 0.0812 and λADC(30) = 0.0406.
We get the probability matrices
NSCC∆t =

0.9984 0 0 0 0 0
0.0016 0.9847 0 0 0 0
0 0.0057 0.9956 0 0 0
0 0 0.0006 1.0000 0 0
0 0.0095 0.0038 0 1.0000 0
0 0 0 0 0 1.0000

and
NADC∆t =

0.9992 0 0 0 0 0
0.0008 0.9847 0 0 0 0
0 0.0057 0.9956 0 0 0
0 0 0.0006 1.0000 0 0
0 0.0095 0.0038 0 1.0000 0
0 0 0 0 0 1.0000

.
We get the time-perturbed cohort
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F (30 + 1/52) = NSCC∆t=1/52(30)Fscreened(30)NADC∆t=1/52(30)
=

0.1995 0.0100 0.0092 0.0100 0.1008 0
0.0102 0.0485 0.0093 0.0099 0.0499 0
0.0028 0.0030 0.0028 0.0028 0.0143 0
0.0100 0.0099 0.0092 0.0100 0.0109 0
0.1572 0.0105 0.0460 0.0173 0.2361 0
0 0 0 0 0 0

.
This computation also served as a control of the MATLAB-computations. Checking that
the computations gave the same result as here verified that the time-progression worked
as expected.
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